AR123961A1 - Composiciones y métodos para el tratamiento de la celiaquía - Google Patents

Composiciones y métodos para el tratamiento de la celiaquía

Info

Publication number
AR123961A1
AR123961A1 ARP210103015A ARP210103015A AR123961A1 AR 123961 A1 AR123961 A1 AR 123961A1 AR P210103015 A ARP210103015 A AR P210103015A AR P210103015 A ARP210103015 A AR P210103015A AR 123961 A1 AR123961 A1 AR 123961A1
Authority
AR
Argentina
Prior art keywords
seq
polypeptide
methods
amino acid
celiac disease
Prior art date
Application number
ARP210103015A
Other languages
English (en)
Spanish (es)
Inventor
Pultz Ingrid Swanson
Clancey Wolf
Siegel Justin Bloomfield
Christine Elaine Tinberg
Lance Stewart
David Baker
Original Assignee
Univ Washington
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Univ California filed Critical Univ Washington
Publication of AR123961A1 publication Critical patent/AR123961A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP210103015A 2020-10-30 2021-10-29 Composiciones y métodos para el tratamiento de la celiaquía AR123961A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063108163P 2020-10-30 2020-10-30

Publications (1)

Publication Number Publication Date
AR123961A1 true AR123961A1 (es) 2023-01-25

Family

ID=78819631

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103015A AR123961A1 (es) 2020-10-30 2021-10-29 Composiciones y métodos para el tratamiento de la celiaquía

Country Status (12)

Country Link
US (1) US20250064903A1 (cg-RX-API-DMAC7.html)
EP (1) EP4237554A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023548083A (cg-RX-API-DMAC7.html)
KR (1) KR20230093323A (cg-RX-API-DMAC7.html)
CN (1) CN116829166A (cg-RX-API-DMAC7.html)
AR (1) AR123961A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021368118A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195929A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006731A2 (cg-RX-API-DMAC7.html)
MX (1) MX2023004807A (cg-RX-API-DMAC7.html)
TW (1) TW202233834A (cg-RX-API-DMAC7.html)
WO (1) WO2022094177A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025068987A1 (en) 2023-09-28 2025-04-03 Takeda Pharmaceutical Company Limited A method of producing a kumamolisin-as polypeptide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE440857T1 (de) * 1998-10-05 2009-09-15 Takeda Pharmaceutical Verfahren zum eliminieren von n-terminalem methionin
JP4475707B2 (ja) * 1998-10-05 2010-06-09 武田薬品工業株式会社 N末端メチオニンの除去方法
LT2718434T (lt) 2011-08-10 2018-08-10 University Of Washington Through Its Center For Commercialization Kompozicijos ir būdai, skirti celiakijos gydymui
US10266815B2 (en) * 2013-08-14 2019-04-23 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
ES2883347T3 (es) * 2014-06-16 2021-12-07 Codexis Inc Composiciones y procedimientos para atenuar y prevenir la inflamación intestinal debida a la presencia de antígenos alimentarios peptídicos en un intestino
TN2017000520A1 (en) * 2015-06-08 2019-04-12 Univ California Compositions and methods for treating celiac sprue disease
MX2019007287A (es) * 2016-12-22 2019-09-27 Ew Nutrition Gmbh Variantes de proteasas estables.

Also Published As

Publication number Publication date
EP4237554A1 (en) 2023-09-06
AU2021368118A1 (en) 2023-05-11
CA3195929A1 (en) 2022-05-05
CO2023006731A2 (es) 2023-06-09
JP2023548083A (ja) 2023-11-15
KR20230093323A (ko) 2023-06-27
WO2022094177A1 (en) 2022-05-05
MX2023004807A (es) 2023-05-10
US20250064903A1 (en) 2025-02-27
TW202233834A (zh) 2022-09-01
AU2021368118A9 (en) 2023-07-06
CN116829166A (zh) 2023-09-29

Similar Documents

Publication Publication Date Title
MX2024015050A (es) L-asparaginasa modificada
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
PE20231439A1 (es) Proteinas f de hmpv estabilizadas por prefusion
MX2020010075A (es) Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.
BR0107703A (pt) Flavivìrus recombinantes e processos para uso dos mesmos
WO2021198706A3 (en) Coronavirus vaccines
AR110502A1 (es) Polinucleótidos y polipéptidos de adenovirus
CO2017008520A2 (es) Variantes de polipéptidos que dividen toxinas de fusarium, aditivo que contiene estas variantes, así como procedimientos para la división de toxinas de fusarium
MX2021011726A (es) Escindasas modificadas, usos de las mismas y kits relacionados.
AR123158A1 (es) Proteínas de fusión del ligando para flt3 y métodos de uso
DE3880739D1 (de) Expression von menschlichem proapolipoprotein a-1.
DE69817211D1 (de) Charakterisierung von polypeptiden
CL2019003406A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
PE20230486A1 (es) Polipeptidos y sus usos
CL2025002422A1 (es) Métodos y composiciones para la administración de sistemas de vector dual otoferlin.
CO2021017664A2 (es) Péptidos
ES8802394A1 (es) Un procedimiento para preparar una proteina de fusion derivada de la secuencia de aminoacidos de la preprorrelaxina humana.
DK611386A (da) Recombinant humant fsh, fremgangsmaade til fremstilling deraf og vektorer og celler til anvendelse ved fremgangsmaaden
ZA202304029B (en) Cxcl9 and variants thereof for immunotherapy of cancer diseases
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
BR112022019571A2 (pt) Método para editar um ácido ribonucleico alvo, domínio dyw, proteína dyw, composição para editar ácido ribonucleico em uma célula eucariótica, ácido nucleico, vetor, e, célula
ES2062982T3 (es) Clonaje y expresion del factor de crecimiento de fibroblasto acido.
ES2076976T3 (es) Metodo para detectar carcinomas de celulas pequeñas y utilizacion de secuencias que codifican acil-peptido hidrolasa para el mismo.
BR112022026248A2 (pt) Conjugados de citocinas
AR123189A1 (es) VACUNA DE SINUCLEÍNA a PARA EL TRATAMIENTO DE SINUCLEINOPATÍAS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal